Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), in patients with homozygous familial hypercholesterolemia (HoFH). The company is currently planning a Phase 3 study to further investigate ARO-ANG3 and intends to conduct a meeting with regulatory authorities in the second half of 2023 to discuss the proposed study design.

The data were presented at the 91^st European Atherosclerosis Society Congress in a poster titled, “ARO-ANG3, an Investigational RNAi Therapeutic, Decreases Serum LDL-Cholesterol, Apolipoprotein B, and Angiopoietin-like Protein 3 in Patients with Homozygous Familial Hypercholesterolaemia,” which may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Javier San Martin, M.D., chief medical officer at Arrowhead, said: “Despite advances in the treatment of cardiovascular disease associated with high LDL-cholesterol, patients with HoFH have a particularly high need for additional therapy with a mechanism working outside of the LDL receptor, such as ANGPTL3 inhibition, and with a dose regimen which can help improve adherence and compliance. The data generated in the GATEWAY study of ARO-ANG3 in patients with HoFH and our prior clinical studies in patient populations with different levels and cause of hypercholesterolemia, demonstrate that ANGPTL3 inhibition led to substantial reductions in LDL-cholesterol, Non-HDL-C, triglycerides, ApoB, and other key lipids and atherogenic lipoproteins. These results are very encouraging and support our plan to rapidly advance ARO-ANG3 into a Phase 3 clinical study in patients with HoFH.”

Key findings from the GATEWAY study include the following:

• At study week 20, administration of 200 mg or 300 mg ARO-ANG3 on day 1 and day 84 led to the following changes:
  • Mean reductions in LDL-C (Martin-Hopkins) of 48.1% and 44.0%, respectively
    • These reductions were achieved on top of continued standard of care, including statins, ezetimibe, PCSK9 inhibitors, and apheresis
  • Mean reductions in ApoB of 39.2% and 34.5%, respectively
  • Mean reductions in ANGPTL3 of 82.7% and 80.1%, respectively
• ANPTL3 inhibition with ARO-ANG3 also reduced HDL-C, non-HDL-C, and triglycerides, consistent with published human genetic data
• Safety and tolerability
  • Overall, no newly identified patterns of adverse events in HoFH patients
  • No treatment emergent adverse events leading to drug discontinuation, dose interruptions, or study withdrawal
  • One serious adverse event of second degree atrioventricular block reported in a patient with extensive atherosclerotic cardiovascular disease history, considered not related to ARO-ANG3

About Homozygous Familial Hypercholesterolemia